Rifampicin-resistant tuberculosis (RR-TB) accounts for an expanding proportion of incident global TB cases and is a major barrier to global tuberculosis control. Conventional therapy for RR-TB is more toxic, less effective, and much more costly than drug-susceptible TB. Treatment success has been...
[1]WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment[M]. Geneva: World Health Organization: 2020. [2]Ahmad N, Ahuja S D, Akkerman O W, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an...
[1]WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment[M]. Geneva: World Health Organization: 2020. [2]Ahmad N, Ahuja S D, Akkerman O W, et al. Treatment co...
世界卫生组织(WHO)2021年发布的全球结核病报告显示,耐多药结核病(MDR-TB)的全球治愈率只有59%,是严重威胁全球公共卫生的重大传染性疾病。临床上MDR-TB患者常因为不恰当的治疗、依从性差、抗结核药物治疗方案不合理等问题导致耐药问题无法得到有效解决[1]。 贝达喹啉(Bedaquiline,Bdq)作为抗结核新药,因其独特的作用机...
BMC Infectious Diseases (2019) 19:733 https://doi.org/10.1186/s12879-019-4378-4 STUDY PROTOCOL Open Access The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens Uzma Khan1* , Helena Huerga2, Aamir J. Khan3, Carole D. Mitnick4,6,7,...
iThe article reports on a study which found that the treatment of multidrug-resistant tuberculosis (MDR-TB) according to the World Health Organization (WHO) guidelines can be cost-effective in both Estonia and the Russian Federation.doi:10.2165/00151234-201206500-00029None...
1.1. MDR-TB and the experience of MDR-TB treatment: background Tuberculosis (TB) is anairborne diseaseand (excepting the COVID-19 pandemic) the leading single-agent infectious cause of mortality worldwide (WHO, 2020a). While TB is curable, treatment is burdensome, requiring six months of ...
, WHO announced changes to treatment guidelines for MDR-TB, including a new priority ranking for available medicines. It urged wider access to the highest-ranked drugs to increase treatment success, including the oral antibiotic bedaquiline, the first drug specifically developed to treat MDR-TB....
适应症:利福平耐药结核病;MDR-TB;XDR-TB;耐药、重症及难治性TB 结核性脑膜炎 :有一定疗效但临床数据有限,剂量和疗程尚未确定 治疗方案:与至少3种对患者分离菌株具有体外敏感性的药物联合组成治疗方案缺少药敏试验,与至少4种可能敏感的药物联合组成治疗方案 ...
MDR-TB Notified among notified MDR-TB TB cases cases MDR-TB enrolled on treatment MDR-TB treatment success MDR-TB DST labs surveillance per 10m / survey pop. Nat Ref Lab Second line drug stock out National Guidelines Approved expansion plan Infection control plan GLOBAL XDR-TB WORLD HEALTH ...